LIF (human, recombinant)

Leukemia inhibitory factor (LIF) is a cytokine and member of the IL-6 family with roles in cell growth and differentiation, bone metabolism, and inflammation. Mature LIF is a 180-amino acid peptide arranged as a four-helix bundle in an up-up-down-down configuration that is synthesized as a 202-amino acid precursor which is post-translationally processed to remove a 22-amino acid signaling sequence from its N-terminus. It is ubiquitously expressed and this expression is commonly upregulated under inflammatory conditions. LIF binds to its receptor LIFRbeta and recruits the IL-6 family common receptor gp130 to form a heterodimer and induce intracellular signaling via the JAK-STAT pathway. Exogenous administration of LIF reduces the rate of deterioration in grip strength and slows progression of the forelimb deformity in the wobbler mouse model of amyotrophic lateral sclerosis (ALS). Intracerebroventricular administration of a recombinant adeno-associated viral vector encoding LIF reduces food intake and body weight gain in rats. Knockdown of Lif induces infertility in female mice. Cayman's LIF (human, recombinant) protein can be used for cell-based assay applications. This protein consists of 180 amino acids, has a calculated molecular weight of 19.7 kDa, and a predicted N-terminus of Ser23 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 35.4 kDa due to glycosylation.Synonyms: Differentiation Inhibitory Factor, HILDA, Human Interleukin in DA Cells, Leukemia Inhibitor Factor, LIF Interleukin 6 Family Cytokine, Melanoma-derived LPL Inhibitor, MLPLI. Purity: >95% estimated by SDS-PAGE. Endotoxin Testing: <1.0 EU/µg, determined by the LAL endotoxin assay. Source: Active recombinant human LIF expressed in HEK293 cells. Amino Acids: 23-202. MW: 19.7 kDa. Formulation: (Request formulation change), Lyophilized from sterile PBS, pH 7.4. UniProt Accession #: P15018.